Multicenter Analysis of Attrition from the Pediatric Tuberculosis Infection Care Cascade in Boston.


Journal

The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410

Informations de publication

Date de publication:
02 2023
Historique:
received: 22 03 2022
revised: 12 08 2022
accepted: 23 09 2022
pubmed: 2 10 2022
medline: 22 3 2023
entrez: 1 10 2022
Statut: ppublish

Résumé

To characterize losses from the pediatric tuberculosis (TB) infection care cascade to identify ways to improve TB infection care delivery. We conducted a retrospective cohort study of children (age <18 years) screened for TB within 2 Boston-area health systems between January 2017 and May 2019. Patients who received a tuberculin skin test (TST) and/or an interferon gamma release assay (IGRA) were included. We included 13 353 tests among 11 622 patients; 93.9% of the tests were completed. Of 199 patients with positive tests for whom TB infection evaluation was clinically appropriate, 59.3% completed treatment or were recommended to not start treatment. Age 12-17 years (vs < 5 years; aOR 1.59; 95% CI, 1.32-1.92), non-English/non-Spanish language preference (vs English; aOR, 1.34; 95% CI, 1.02-1.76), and receipt of an IGRA (vs TST, aOR, 30.82; 95% CI, 21.92-43.34) were associated with increased odds of testing completion. Odds of testing completion decreased as census tract social vulnerability index quartile increased (ie, social vulnerability worsened; most vulnerable quartile vs least vulnerable quartile, aOR, 0.77; 95% CI, 0.60-0.99). Odds of completing treatment after starting treatment were higher in females (vs males; aOR, 2.35; 95% CI, 1.14-4.85) and were lower in patients starting treatment in a primary care clinic (vs TB/infectious diseases clinic; aOR, 0.44; 95% CI, 0.27-0.71). Among children with a high proportion of negative TB infection tests, completion of testing was high, but completion of evaluation and treatment was moderate. Transitions toward IGRA testing will improve testing completion; interventions addressing social determinants of health are important to improve treatment completion.

Identifiants

pubmed: 36181869
pii: S0022-3476(22)00860-5
doi: 10.1016/j.jpeds.2022.09.038
pmc: PMC10334304
mid: NIHMS1914951
pii:
doi:

Types de publication

Multicenter Study Journal Article Research Support, U.S. Gov't, P.H.S. Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

181-188.e5

Subventions

Organisme : NIMH NIH HHS
ID : K24 MH114732
Pays : United States
Organisme : AHRQ HHS
ID : T32 HS000063
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Références

Lancet Infect Dis. 2016 Nov;16(11):1269-1278
pubmed: 27522233
Eur Respir J. 2020 Mar 20;55(3):
pubmed: 31980498
Clin Infect Dis. 2022 Nov 14;75(10):1792-1799
pubmed: 35363249
J Environ Health. 2018 Jun;80(10):34-36
pubmed: 32327766
Am J Respir Crit Care Med. 2016 Aug 15;194(4):501-9
pubmed: 26866439
Lancet. 2019 May 25;393(10186):2168-2174
pubmed: 30981536
Geospat Health. 2011 May;5(2):265-73
pubmed: 21590677
Int J Tuberc Lung Dis. 2017 Jun 1;21(6):610-623
pubmed: 28482955
Int J Infect Dis. 2014 Jun;23:4-7
pubmed: 24657274
Ann Surg Oncol. 2021 Apr;28(4):1918-1926
pubmed: 33057860
PLoS Med. 2019 Feb 27;16(2):e1002754
pubmed: 30811385
PLoS One. 2017 Aug 1;12(8):e0182185
pubmed: 28763500
Int J Tuberc Lung Dis. 2015 Jul;19(7):799-804
pubmed: 26056104
Health Educ Q. 1988 Winter;15(4):351-77
pubmed: 3068205
Clin Infect Dis. 2021 Nov 2;73(9):e3531-e3535
pubmed: 33242078
BMC Infect Dis. 2020 May 18;20(1):352
pubmed: 32423422
BMC Public Health. 2017 Jun 2;17(1):538
pubmed: 28578689
Health Policy Plan. 2020 Oct 1;35(8):1130-1132
pubmed: 32832996
Am J Public Health. 2018 Nov;108(S4):S242-S245
pubmed: 30383424
BMJ Glob Health. 2021 May;6(5):
pubmed: 34016576
Clin Infect Dis. 2017 Jan 15;64(2):111-115
pubmed: 28052967
Matern Child Health J. 2006 Mar;10(2):171-6
pubmed: 16496221
PLoS One. 2020 Dec 3;15(12):e0243102
pubmed: 33270737
PLoS One. 2021 Apr 1;16(4):e0249012
pubmed: 33793612
Surgery. 2021 Aug;170(2):571-578
pubmed: 33775393
Pediatrics. 2019 Jun;143(6):
pubmed: 31147487
J Infect Public Health. 2010;3(2):67-75
pubmed: 20701894
Pediatr Clin North Am. 2017 Aug;64(4):893-909
pubmed: 28734517
J Pediatr. 2015 May;166(5):1240-1245.e1
pubmed: 25720366
Int J Tuberc Lung Dis. 2014 Jun;18(6):640-6
pubmed: 24903932
Pediatrics. 1997 Aug;100(2 Pt 1):210-3
pubmed: 9240801
MMWR Recomm Rep. 2020 Feb 14;69(1):1-11
pubmed: 32053584
Pediatrics. 2020 Jan;145(1):
pubmed: 31892521
J Surg Res. 2019 Nov;243:160-164
pubmed: 31177035
Int J Tuberc Lung Dis. 2014 Dec;18(12):1449-54
pubmed: 25517810
Eur Respir J. 2018 Jul 11;52(1):
pubmed: 29748305
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810

Auteurs

Jeffrey I Campbell (JI)

Division of Infectious Diseases, Boston Children's Hospital, Boston, MA. Electronic address: Jeffrey.campbell@childrens.harvard.edu.

Mary Tabatneck (M)

Department of Pediatrics, Boston Children's Hospital, Boston, MA.

Mingwei Sun (M)

Center for Research Information Technology, Boston Children's Hospital, Boston, MA.

Wei He (W)

Center for Research Information Science and Computing, Massachusetts General Hospital, Boston, MA.

Nicholas Musinguzi (N)

Global Health Collaborative, Mbarara University of Science and Technology, Mbarara, Uganda.

Bethany Hedt-Gauthier (B)

Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA.

Gabriella S Lamb (GS)

Division of Infectious Diseases, Boston Children's Hospital, Boston, MA.

Kezia Domond (K)

Center for Global Health, Massachusetts General Hospital, Boston, MA.

Don Goldmann (D)

Division of Infectious Diseases, Boston Children's Hospital, Boston, MA.

Vishakha Sabharwal (V)

Division of Pediatric Infectious Diseases, Boston Medical Center, Boston, MA.

Thomas J Sandora (TJ)

Division of Infectious Diseases, Boston Children's Hospital, Boston, MA.

Jessica E Haberer (JE)

Center for Global Health, Massachusetts General Hospital, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH